Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE: Epoprostenol as Adjunct Anticoagulation in Pediatric ECMO
NCT07837869Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of epoprostenol in Extracorporeal membrane oxygenation (ECMO) (6 arms). Primary endpoint: Safety and Maximum Tolerated Dose at 72 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
epoprostenol
03
Conditions
Extracorporeal membrane oxygenation (ECMO)
Beyond the preview
Go deeper on NCT07837869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07837869.